RecruitingPhase 1NCT06062745

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

A Pilot Study for Detection of PSMA-Low Castration Resistant and Neuroendocrine Prostate Cancer With 18F-fluciclovine PET/CT Imaging

Sponsor

Brigham and Women's Hospital

Enrollment

30 participants

Start Date

Feb 1, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Prostate Cancer Metastatic Prostate Cancer Metastatic Prostate Neuroendocrine Carcinoma

Summary

This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features. The name of the study interventions are: * 18F-fluciclovine-PET/CT scan * Two research blood collections

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This pilot study is using a PET/CT scan with a tracer called fluciclovine to detect a specific subtype of advanced prostate cancer — neuroendocrine prostate cancer or PSMA-low castration-resistant disease — which is harder to detect on the standard PSMA scans used for most prostate cancers. **You may be eligible if...** - You have confirmed metastatic prostate cancer - You either have low PSMA expression on a recent PSMA-PET/CT scan with at least 5 metastatic lesions, OR you have neuroendocrine prostate cancer confirmed by biopsy **You may NOT be eligible if...** - Your prostate cancer has normal or high PSMA expression - You do not have confirmed metastatic disease - You have other conditions that prevent safe participation in the scan Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG18F-fluciclovine

18F-fluciclovine is a radiotracer targeting amino-acid transporters.Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance to make images of processes that are happening in the body

DEVICEPET/CT

Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.